INJECTABLE DRUGS MARKET ANALYSIS

Global injectable drugs market growth can be hampered due to risk of infections and side effects associated with injections. Injections can occasionally cause infections like sepsis, cellulitis or abscesses at the injection site, if proper sterile procedures are not followed. Injections may also cause hematomas, ulcers or nerve damage at the injection site. Intravenous injections carry higher risks, if contaminated fluids enter the bloodstream. Self-injecting medications like insulin at home also entails the risk of accidental needle sticks, which could potentially spread blood-borne infections like HIV, hepatitis B or C. Side effects of injectable drugs could range from mild reactions like pain, redness, swelling at the injection site to life-threatening systemic allergic reactions or anaphylaxis in sensitive individuals. The risks associated with injections makes them unpopular options as compared to oral medications.

Market Opportunities: Emergence of biosimilars for market

The emergence of biosimilars presents a major growth opportunity for the global injectable drugs market. Biosimilars are biological products that are similar to an already approved biological reference product known as the originator biologic. As patents of many blockbuster biologics expire, multiple pharmaceutical companies are developing biosimilars of those products. This increases treatment options for patients and physicians apart from lowering healthcare costs significantly compared to originator biologics. The uptake of affordable biosimilars is expected to be faster in the injectable segment as parenteral administration remains the preferred route for many monoclonal antibody drugs and other biologics. The biosimilars market is projected to grow substantially in the near future, thus, creating abundant opportunities for injectable drug manufacturers. This can enhance access to lifesaving therapies and propel the expansion of the worldwide injectable drugs market.